Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls

Health and Quality of Life Outcomes

Xiaomei Zhang³  Zhenhao Ji³  Kaina Zhou³  Qian Wu³  Yaling Guo²  Yong Liu¹  Min Zhang³  Guihua Zhuang³ 

[1] Xi’an Jiaotong University Health Science Center, No. 76 West Yanta Road, Xi’an, Shaanxi 710061, China;The Eighth Hospital of Xi’an, No. 2 East Zhangba Road, Xi’an, Shaanxi 710061, China;Department of Epidemiology and Biostatistics, School of Public Heath, Xi’an Jiaotong University Health Science Center, No. 76 West Yanta Road, Xi’an, Shaanxi 710061, China

关键词: Mainland Chinese;    Preference;    Chronic Liver Disease Questionnaire;    Short Form 36 version 2;    Health-related quality of life;    Chronic hepatitis B;   

Others  :  814609
DOI  :  10.1186/1477-7525-12-101

 received in 2014-03-06, accepted in 2014-06-08,  发布年份 2014

【 摘 要 】

Objective

Few studies have evaluated health-related quality of life (HRQoL) of patients with chronic hepatitis B (CHB) in mainland China. We aimed at characterizing the impact of CHB on HRQoL in mainland Chinese and finding out factors associated with HRQoL.

Methods

460 CHB patients (323 with CHB only, 54 with compensated cirrhosis and 83 with decompensated cirrhosis) and 460 pair-matched healthy controls were recruited in Xi’an city. They answered a structured questionnaire including the Short Form 36 version 2 (SF-36v2), the Chronic Liver Disease Questionnaire (CLDQ) (only for patients), and questions on socio-demographic and clinical characteristics. A blood sample was collected from each of patients for liver function tests. SF-36v2 scores were compared between patients and controls overall and by groups by paired-samples t-test, and CLDQ scores and paired differences of SF-36v2 scores were compared among three patient groups by one-way ANOVA or Kruskal-Wallis test. Multi-variable linear regression analyses were performed to identify determinants of HRQoL in patients.

Results

Patients, overall and by groups had significantly lower SF-36v2 scores than controls on all summaries and domains, with differences higher than the suggested minimally important difference values. Both the SF-36v2 and the CLDQ showed that HRQoL of patients with cirrhosis further deteriorated, but compensated and decompensated cirrhosis patients had similar total HRQoL impairments. The gradually increasing impairment with disease progression was confirmed only on physical components. Impaired liver function and currently taken anti-viral treatment were associated with lower HRQoL. Education attainment and annual per capita household income had a positive effect on HRQoL.

Conclusions

Mainland Chinese CHB patients suffered significant HRQoL impairment on all health dimensions, and the impairment reached a high level on mental health at initial stage of illness and increased gradually on physical health with disease progression. Attention should be paid to the reduction of patients’ treatment cost burden and the provision of early health education accompanied with proper treatments.

【 授权许可】

   
2014 Zhuang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y: Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
• [2]Lu FM, Li T, Liu S, Zhuang H: Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat 2010, 17(Suppl 1):4-9.
• [3]Liu J, Fan D: Hepatitis B in China. Lancet 2007, 369:1582-1583.
• [4]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
• [5]Testa MA, Simonson DC: Assesment of quality-of-life outcomes. N Engl J Med 1996, 334:835-840.
• [6]Fayers PM, Machin D: Quality of Life: The Assessment, Analysis, and Interpretation of Patient-reported Outcomes. 2nd edition. John Wiley & Sons Ltd; 2007. ISBN: 0-470-02450-X
• [7]Ong SC, Mak B, Aung MO, Li SC, Lim SG: Health-related quality of life in chronic hepatitis B patients. Hepatology 2008, 47:1108-1117.
• [8]Lam ETP, Lam CLK, Lai CL, Yuen MF, Fong DYT, So TMK: Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes 2009, 7:52-61. BioMed Central Full Text
• [9]Ozkan M, Corapçioglu A, Balcioglu I, Ertekin E, Khan S, Ozdemir S, Karayün D, Unsalver BO, Kocaman N, Kaymakglu S, Köroglu G: Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006, 36:283-297.
• [10]Altindag A, Cadirci D, Sirmatel F: Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers. Neurosciences (Riyadh) 2009, 14:56-59.
• [11]Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, Younossi ZM: Health-related quality of life in patients with chronic hepatitis B. Liver Int 2007, 27:1119-1125.
• [12]Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH: The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008, 11:527-538.
• [13]Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes. 5th edition. New York: Oxford University Press; 2005.
• [14]Farkas JD, Farkas P: Liver and Gastroenterology Tests. In Basic Skills in Interpreting Laboratory Data. 4th edition. Edited by Lee M. Bethesda: ASHP; 2009:235-244.
• [15]Maruish ME: User’s Manual for the SF-36v2 Health Survey. 3rd edition. Lincoln RI: QualityMetric Incorporated; 2011.
• [16]Zhou KN, Zhang M, Wu Q, Ji ZH, Zhang XM, Zhuang GH: Reliability, validity and sensitivity of the Chinese (simple) short form 36 health survey version 2 (SF-36v2) in patients with chronic hepatitis B. J Viral Hepat 2013, 20:e47-e55.
• [17]Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292.
• [18]Lam CLK, Brazier J, McGhee SM: Valuation of the SF-6D health states is feasible, acceptable, reliable, and valid in a Chinese population. Value Health 2008, 11:295-303.
• [19]Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45:295-300.
• [20]Zhou KN, Zhang M, Wu Q, Ji ZH, Zhang XM, Zhuang GH: Psychometrics of chronic liver disease questionnaire in Chinese chronic hepatitis B patients. World J Gastroenterol 2013, 19:3494-3501.
• [21]Foster GR: Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999, 31(Suppl 1):250-254.
• [22]Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD: Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005, 11:7494-7498.
• [23]Hu M, Chen W: Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009, 12(Suppl 3):89-92.
• [24]Wang Y, Jia J: Control of hepatitis B in China: prevention and treatment. Expert Rev Anti Infect Ther 2011, 9:21-25.